One patient had grade 3 myalgia requiring narcotics after each dose of rituximab but was able to take all eight planned doses. Rituximab may also have a role in treatment of minimal residual disease. BL-22 is composed of the variable domains of the RFB4 monoclonal antibody to CD22, fused to the same Pseudomonas toxin. Toxicities included reversible transaminase elevations, fever, and hypoalbuminemia. BL-22 produced CR in 3 of 7 patients and PR in 2 of 7 patients.
Complete responses appear durable.
Inc. All rights reserved.